$GALT insider trading
Over the last 12 months, Galectin Therapeutics insiders reported 4 buys totaling $26K and 27 sales totaling $6.1M across SEC Form 4 filings. 81% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $26K 4 events
- Sold · 12m
- $6.1M 27 events
- Events · 12m
- 31 Form 4 filings, grouped
- Insiders · 12m
- 7 distinct reporters
- 10b5-1 share
- 81% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | Jamil KhurramChief Medical Officer · O | ▼ Sale | 16,250 | $5.13 | $83K | -100% | plan |
| Jun 29, 2026 | Shlevin Harold H.D | ▼ Sale | 30,000 | $5.03 | $151K | -82.2% | plan · 2 tranches |
| Jun 29, 2026 | Jamil KhurramChief Medical Officer · O | ▼ Sale | 52,037 | $5.04 | $262K | -100% | plan · 3 tranches |
| Jun 23, 2026 | Jamil KhurramChief Medical Officer · O | ▼ Sale | 7,557 | $3.14 | $24K | -100% | plan |
| May 26, 2026 | Jamil KhurramChief Medical Officer · O | ▼ Sale | 568 | $3.1 | $2K | -100% | plan |
| Feb 6, 2026 | ELDRED KARYD | ▲ Buy | 300 | $2.7 | $810 | +0.5% | — |
| Jan 6, 2026 | LEWIS JOELPresident and CEO · O·D | ▼ Sale | 84,000 | $3.82 | $321K | -9.2% | plan · 3 tranches |
| Jan 6, 2026 | CALLICUTT JACK WChief Financial Officer · O | ▼ Sale | 60,000 | $3.89 | $233K | -88.7% | plan · 3 tranches |
| Jan 6, 2026 | Jamil KhurramChief Medical Officer · O | ▼ Sale | 60,000 | $3.87 | $232K | -100% | plan · 3 tranches |
| Dec 31, 2025 | Jamil KhurramChief Medical Officer · O | ▼ Sale | 8,125 | $4.07 | $33K | -100% | plan |
| Dec 23, 2025 | ELDRED KARYD | ▲ Buy | 700 | $3.73 | $3K | +1.1% | — |
| Dec 23, 2025 | FREEMAN KEVIN DD | ▲ Buy | 5,500 | $3.55 | $20K | +11.1% | plan |
| Dec 23, 2025 | ELDRED KARYD | ▲ Buy | 700 | $3.73 | $3K | +1.1% | plan |
| Dec 17, 2025 | LEWIS JOELPresident and CEO · O·D | ▼ Sale | 7,829 | $7.06 | $55K | -0.9% | plan |
| Dec 17, 2025 | Jamil KhurramChief Medical Officer · O | ▼ Sale | 19,442 | $7.04 | $137K | -100% | plan · 3 tranches |
| Dec 17, 2025 | Shlevin Harold H.D | ▼ Sale | 24,499 | $7.04 | $172K | -79% | plan · 2 tranches |
| Dec 16, 2025 | 10X Fund, L.P.10% | ▼ Sale | 30,681 | $6.66 | $204K | -0.5% | — |
| Dec 15, 2025 | Shlevin Harold H.D | ▼ Sale | 28,210 | $6.28 | $177K | -71.6% | plan · 2 tranches |
| Dec 9, 2025 | Shlevin Harold H.D | ▼ Sale | 175,790 | $6 | $1.1M | -94% | plan · 8 tranches |
| Dec 3, 2025 | 10X Fund, L.P.10% | ▼ Sale | 150,000 | $5.68 | $852K | -2.6% | 2 tranches |
| Nov 18, 2025 | LEWIS JOELPresident and CEO · O·D | ▼ Sale | 22,463 | $6.07 | $136K | -2.6% | plan · 2 tranches |
| Nov 18, 2025 | CALLICUTT JACK WChief Financial Officer · O | ▼ Sale | 77,920 | $6.15 | $479K | -91.1% | plan · 5 tranches |
| Nov 13, 2025 | Jamil KhurramChief Medical Officer · O | ▼ Sale | 121,117 | $5.47 | $663K | -96.4% | plan · 4 tranches |
| Nov 11, 2025 | 10X Fund, L.P.10% | ▼ Sale | 40,000 | $5.25 | $210K | -0.7% | — |
| Nov 10, 2025 | LEWIS JOELPresident and CEO · O·D | ▼ Sale | 1,867 | $6.03 | $11K | -0.2% | plan |
| Nov 10, 2025 | CALLICUTT JACK WChief Financial Officer · O | ▼ Sale | 5,291 | $6.03 | $32K | -41% | plan · 3 tranches |
| Nov 5, 2025 | LEWIS JOELPresident and CEO · O·D | ▼ Sale | 200 | $6 | $1K | — | plan |
| Nov 5, 2025 | CALLICUTT JACK WChief Financial Officer · O | ▼ Sale | 600 | $6 | $4K | -7.3% | plan · 3 tranches |
| Nov 4, 2025 | LEWIS JOELPresident and CEO · O·D | ▼ Sale | 15,720 | $6.07 | $95K | -1.9% | plan · 2 tranches |
| Nov 4, 2025 | CALLICUTT JACK WChief Financial Officer · O | ▼ Sale | 32,439 | $6.06 | $197K | -81% | plan · 6 tranches |
| Oct 22, 2025 | 10X Fund, L.P.10% | ▼ Sale | 50,000 | $4.94 | $247K | -0.8% | 2 tranches |
| Sep 12, 2025 | CALLICUTT JACK WChief Financial Officer · O | ▼ Sale | 8,706 | $6.44 | $56K | -53.3% | plan |
| Sep 12, 2025 | LEWIS JOELPresident and CEO · O·D | ▼ Sale | 14,000 | $6.36 | $89K | -1.7% | plan |
Every $GALT filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Galectin Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $GALT feed.